Holger Stark is a pharmacist by education and completed his Ph.D. in Medicinal Chemistry under the supervision of Prof. W. Schunack at the Free University of Berlin, Germany, in 1991 on newly designed prodrugs (BF2.94). During his habilitation at the same university, he worked on neurotransmitter ligands, mainly for dopamine and histamine receptor subtypes for the central nervous system. In 2000, he became a full professor at Goethe University in Frankfurt, Germany, and, in 2013, moved to Heinrich Heine University in Düsseldorf, Germany, where he is currently based. He has founded some start-up companies on cancer therapeutics (Warburg Glycomed and PSites Pharma) and has received several prizes for his successful research, as well as for teaching. In 2016, he received an honorary doctorate from the University of Nis, Serbia. He is a co-inventor of pitolisant (Wakix®, Ozawade), the first histamine H3 receptor antagonist with market approval, and has prepared some backup (pre)clinical candidates in different leads for various targets. From 2004 to 2019, he was editor-in-chief of the Archiv der Pharmazie–Chemistry in Life Sciences, one of the oldest journals on Medicinal Chemistry.
Research Keywords & Expertise
Drug Development
Drug Discovery
Medicinal Chemistry
medicinal chemistry dr...
Neurotransmitter
Short Biography
Holger Stark is a pharmacist by education and completed his Ph.D. in Medicinal Chemistry under the supervision of Prof. W. Schunack at the Free University of Berlin, Germany, in 1991 on newly designed prodrugs (BF2.94). During his habilitation at the same university, he worked on neurotransmitter ligands, mainly for dopamine and histamine receptor subtypes for the central nervous system. In 2000, he became a full professor at Goethe University in Frankfurt, Germany, and, in 2013, moved to Heinrich Heine University in Düsseldorf, Germany, where he is currently based. He has founded some start-up companies on cancer therapeutics (Warburg Glycomed and PSites Pharma) and has received several prizes for his successful research, as well as for teaching. In 2016, he received an honorary doctorate from the University of Nis, Serbia. He is a co-inventor of pitolisant (Wakix®, Ozawade), the first histamine H3 receptor antagonist with market approval, and has prepared some backup (pre)clinical candidates in different leads for various targets. From 2004 to 2019, he was editor-in-chief of the Archiv der Pharmazie–Chemistry in Life Sciences, one of the oldest journals on Medicinal Chemistry.
Advance your academic career, collaborate globally, and expand your network—
join now
!
Well done!
